Modifying microbes for clot prevention
Cleveland Clinic researchers have developed inhibitors of bacterial choline trimethylamine-lyase (bacterial cutC), an enzyme found in commensal gut microbes, that could help treat thrombosis by targeting bacterial metabolic activity without killing the microbes.
Previous studies identified a metabolic pathway mediated by the gut microbiome that generates the metabolite trimethylamine N-oxide (TMAO), which increases platelet responsiveness and the risk of developing diet-induced cardiovascular and renal diseases. In 2015, the Cleveland Clinic researchers used 3,3-dimethyl-1-butanol (DMB), a naturally occurring choline analog, to inhibit upstream TMAO precursor trimethylamine (TMA) and reduce atherosclerotic plaques in animal models of atherosclerosis (see "The Gut of Heart Disease")...
BCIQ Company Profiles
BCIQ Target Profiles